Loading term…
A US NDA pathway that relies, at least in part, on published literature or FDA findings for an approved drug, plus new data to bridge differences for the applicant’s product.
A new extended-release formulation is submitted using literature plus bridging PK studies and limited clinical data.
FD&C Act 505(b)(2)